<DOC>
	<DOCNO>NCT00537277</DOCNO>
	<brief_summary>This trial conduct Europe . This clinical trial investigate effectiveness safety use biphasic insulin aspart 30 initiation intensification insulin treatment type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 Type 2 Diabetes Mellitus When Failing OADs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 Diabetes Mellitus 12 month HbA1c : 7.5 11.0 % An antidiabetic regimen stable least 3 month prior screen An antidiabetic regimen include minimum 2 oral antidiabetic drug ( OADs ) 1 OAD plus even bedtime basal insulin OADs dose 50 % maximum recommend dose Use insulin preparation NPH glargine within past 6 month Use 60 unit insulin per day Morning time insulin administration Use one insulin dose daily</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>